Search
Alzheimer's Disease Paid Clinical Trials in Maryland
A listing of 18 Alzheimer's Disease clinical trials in Maryland actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 18
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Dementia
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Alzheimer's Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
The Redwood Study is currently enrolling adults 18 to 75 years of age with Alpha-1
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
All
Ages:
Between 40 years and 64 years
Trial Updated:
11/06/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome
Recruiting
The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.
Gender:
All
Ages:
25 years and above
Trial Updated:
11/06/2023
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Alzheimer's Disease in Down Syndrome
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
11/03/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Recruiting
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging. Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to patients, caregivers, and society and are near-universal at some point in the AD course. One of the most troubling of these symptoms is agitation (Agit-AD), typified by a variety of problem behaviors including combativeness, yelling, pacing, lack of cooperation with care, insomnia, and restlessness. There is a great need for better interventions... Read More
Gender:
All
Ages:
Between 60 years and 95 years
Trial Updated:
10/23/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Alzheimer's Disease
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Recruiting
Background:
About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.
Objective:
To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.
Eligibility:
Adults age 18 years and older in good general he... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
10/21/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
10/16/2023
Locations: Optum Infusion - Columbia, Columbia, Maryland +1 locations
Conditions: Alzheimer Disease
IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's
Recruiting
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
Gender:
All
Ages:
60 years and above
Trial Updated:
10/16/2023
Locations: Site 400, Baltimore, Maryland
Conditions: Alzheimer Disease, Agitation,Psychomotor, Depression, Anxiety, Memory Impairment, Care Giving Burden, NPS, Agitated; State, Acute Reaction to Stress, Aggression, Aggressive Outburst
TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort.
If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstud... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
10/09/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Recruiting
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Gender:
All
Ages:
All
Trial Updated:
09/21/2023
Locations: Centers for Medicare and Medicaid Services, Baltimore, Maryland
Conditions: Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
Recruiting
Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating synaptic damage that correlates with cognitive decline in AD patients. Transcranial Direct Current Stimulation (tDCS) is a safe, non-invasive, non-painful electrical stimulation of the brain that is shown to act as a primer at the synaptic level when administered along wit... Read More
Gender:
All
Ages:
Between 50 years and 75 years
Trial Updated:
09/15/2023
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Recruiting
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.
Gender:
All
Ages:
Between 55 years and 85 years
Trial Updated:
09/14/2023
Locations: PharmaSite Research, Baltimore, Maryland
Conditions: Alzheimer Disease, Dementia of Alzheimer Type
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Recruiting
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/09/2023
Locations: Behavioral Pharmacology Research Unit, Baltimore, Maryland
1 - 12 of 18